What's Hot
View all perspectives
Dr. John Cush RheumNow
1 year 4 months ago
ICYMI: The Biosimilar "Buy In"
In 2023, we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.
https://t.co/U7YTH0Uodf https://t.co/PZelN4G5Jb
Interstitial lung disease (ILD) is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis. While for a long time RA treatments, such as methotrexate (MTX), have been considered a risk factor, recent data have shown the innocuity of MTX on lung disease (and in fact suggests it could reduce risk of ILD by increasing disease control and remission).
Dr. Antoni Chan synovialjoints
1 year 4 months ago
A highlight at #EULAR2023 AI in predicting RA from MRI scans of hands and feet in patients with early onset arthritis or clinically suspect arthralgia. From 1,974 people, 651 went on to develop RA. The accuracies were close to expert level prediction, Li Y, Abst#OP0002 @RheumNow https://t.co/MP8yn18PWI
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 4 months ago
#EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were:
- Current/former renal involvement
- high baseline proteinuria
- hypoalbuminaemia
- low C3
@RheumNow https://t.co/vylWCf0XNy
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Aurelie Najm AurelieRheumo
1 year 4 months ago
Beydon et al., french registry study 255000+ RA patients 2010-2020
Increase ⬆️ overall malignancy by 20% vs. general pop
⬆️lung 40%, ENT 40%, cervix 80%, prostate 8%, melanoma 37%
Pancreatic cancer 10% less frequent in ♂
Breast 9% & Uterine body 23% less frequent in ♀
David Liew drdavidliew
1 year 4 months ago
So can computers beat humans in predicting RA from pre-RA arthralgia MRIs?
No, for now… but unsupervised they pick up the same culpable features we look for: bone marrow edema & tenosynovitis. Sometimes it’s nice when the machines tell us we’re right
#EULAR2023 OP0002 @RheumNow https://t.co/71Zo2JyC8d
Aurelie Najm AurelieRheumo
1 year 4 months ago
I swear it is muscle, Doctor!
GLORIA trial substudy
Pred 5 mg/day 2 years in RA pts >65yo:
Weight gain 1kg vs. PBO, no increase or redistribution of fat mass but augmentation in lean mass 💪
Probably explained by better disease control (although NS in study, small sample size)
Aurelie Najm AurelieRheumo
1 year 4 months ago
Mild correlation between fine motor hand skills and synovitis score grey scale and PD
However no correlation w/ TJC68/SJC66 https://t.co/ryCs21KRcB
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 4 months ago
#EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed primary endpoint (=>50% reduction in proteinuria) was met more in Bari vs Cyclo at Wks12 & 24. Intriguing but need longer-term, composite endpoint and larger size! @RheumNow https://t.co/z3YJog6gTy
Aurelie Najm AurelieRheumo
1 year 4 months ago
Loss of grip strength in PsA is NOT correlated w/ clinical parameters but US features
US study of 100+ pts w/ Pso or PsA
Strong correlation grip strength & grey scale tenosynovitis score (digit 2) r=-0.6
https://t.co/qClfMrhqhI OP0069 #EULAR23 @Rheumnow
Dr. Antoni Chan synovialjoints
1 year 4 months ago
EULAR imaging recommendations in gout - ultrasound and DECT are recommended, double contour sign useful, by Peter Mandl, Abstr#0008 @RheumNow https://t.co/BNd1S3AJpB
Aurelie Najm AurelieRheumo
1 year 4 months ago
EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer
1) If remission, initiate targeted therapy w/out delay
2) Prefer anti-cytokine bDMARDs if Hx solid cancer
3) B cell depleting therapy if Hx lymphoma
4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 4 months ago
#EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were:
- Current/former renal involvement
- high baseline proteinuria
- hypoalbuminaemia
- low C3
@RheumNow https://t.co/bBtBm1olcr
Dr. John Cush RheumNow
1 year 4 months ago
Belimumab in Lupus Nephritis
Belimumab is a BLyS-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
https://t.co/f2odJWlyR2 https://t.co/y5exJIFzht
Poster Hall